NCT04031677 2026-03-18
STRASS2
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Recruiting
Clinical Trials
20 trialsNCT06422806 2026-03-18
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT06568172 2026-03-18
Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT06088290 2026-03-11
SaLuDo
PharmaMar
Phase 3 Recruiting
NCT05235165 2026-02-27
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
Children's Oncology Group
Phase 3 Recruiting
NCT05304585 2026-02-24
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
Children's Oncology Group
Phase 3 Recruiting
NCT07174427 2026-02-18
Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma
Takara Bio Inc.
Phase 3 Recruiting
NCT04307277 2026-02-11
CHIC-STS01
Institut Claudius Regaud
Phase 3 Recruiting
NCT07218926 2026-01-30
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
GlaxoSmithKline
Phase 3 Recruiting
NCT06220032 2026-01-05
HO170DLBCL
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Recruiting
NCT06881992 2025-12-30
Tumor HI
Rezolute
Phase 3 Recruiting
NCT03422198 2025-12-12
SAVE
University of Utah
Phase 3 Recruiting
NCT05646316 2025-10-08
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
NRG Oncology
Phase 3 Recruiting
NCT03805022 2025-10-02
CIRSARC
Institut Bergonié
Phase 3 Recruiting
NCT05597917 2025-04-04
TRABTRAP
Universität Münster
Phase 3 Recruiting
NCT06836492 2025-02-20
A Prospective Clinical Cohort Study on Stratified Treatment of Rhabdomyosarcoma Based on Risk Factors.
Sun Yat-sen University
Phase 3 Recruiting
NCT06640361 2024-12-27
A Study of Olverembatinib in SDH-deficient GIST.
Ascentage Pharma Group Inc.
Phase 3 Recruiting
NCT06669013 2024-11-01
FollowTheDIN
N.N. Petrov National Medical Research Center of Oncology
Phase 3 Recruiting
NCT04650984 2024-04-08
FIBROSARC
Philogen S.p.A.
Phase 3 Recruiting
NCT05328258 2023-10-27
ProFertil
Karolinska University Hospital
Phase 3 Recruiting